SC-CAPITAL-PARTNERS
SC Capital Partners, a Singapore-based institutional real estate private equity investment firm, is pleased to announce the final closing of its fourth real estate private equity fund, Real Estate Capital Asia Partners IV L.P. (“RECAP IV”), with $850 million of total equity commitments.
RECAP IV held its final closing on December 5, 2014, merely three months following its first closing, raising capital from a diverse array of institutional investors from across the globe, including public and private pension funds, funds of funds, endowments, asset managers, private foundations, family offices and insurance companies. The fund will have an investment theme similar to its predecessor fund, focusing on acquiring a portfolio of pan-Asian real estate and real estate-related investments through a disciplined investment approach targeting undervalued, undermanaged and distressed assets and situations.
“We believe RECAP IV is well positioned to take advantage of the investment opportunity in this diverging world environment, and we are pleased to have support from a global investor base,” said Suchad Chiaranussati, Chairman of SC Capital Partners. Limited partners in RECAP IV comprise 34 institutional investors from North America, Europe, Asia and Australia.
“We are delighted to have worked again with the SC Capital Partners team and are very proud to be associated with such a first-class organization,” said Frank Schmitz, Senior Managing Director of Park Hill Group LLC (“Park Hill”), who served as the exclusive placement agent on the RECAP IV capital raise. Park Hill previously worked with SC Capital Partners in the formation of Real Estate Capital Asia Partners III L.P. and Real Estate Capital Asia Partners II L.P. Both funds have been recognized as one of the top-performing real estate private equity funds within their respective vintage years, as reported by Preqin as of January 2015.
RECAP IV has completed two investments as of December 31, 2014, including a retail asset in Melbourne, Australia, and an interest in prime beachfront land in the Phang Nga Province of Thailand.
About SC Capital Partners
Formed in 2004, SC Capital Partners is a 100% employee-owned, pan-Asian real estate private equity investment firm headquartered in Singapore. The firm pursues opportunistic real estate investments throughout Asia, focusing on acquiring, developing, redeveloping and operating real estate and real estate-related assets that are undervalued, undermanaged or whose situation are distressed and where value creation opportunities arise from market inefficiencies and/or strong macroeconomic fundamentals. The firm has built a successful track record over the past decade through its investments in multiple property types, including office, retail, multifamily, hospitality and mixed-use assets, across various markets throughout Asia-Pacific: China, Hong Kong, Japan, Singapore, South Korea, Australia, Thailand and Myanmar. Since inception, SC Capital Partners has invested more than $870 million of equity and just under $1.8 billion of total capital across 39 distinct transactions on behalf of its four institutional real estate private equity funds.
Contact:
SC Capital Partners
Suchad Chiaranussati, +65-6887-5800
suchadc@recapinvestments.com
Liwen
Ho, +65-6887-5800
liwen@recapinvestments.com
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum